Biotech News

CorMedix Therapeutics Provides Business Update, Reaffirms 2026 Total Revenue Guidance, and Reports Third Quarter Cash Position

CorMedix Inc. (CRMD)CorMedix Inc.Earnings

CorMedix Therapeutics (Nasdaq: CRMD) today provided a business update in advance of a conference call expected to be held on November 12, 2026 to discuss the Company’s complete quarterly financial performance.

Related news

CorMedix Inc.

Institutional Anti-Infective Company CorMedix Therapeutics develops and commercializes products used in hospitals, dialysis clinics, infusion centers, and other institutional settings of care. DefenCath DefenCath is a taurolidine and heparin catheter-lock solution used to reduce catheter-related bloodstream infections in adult...

Recent company news

Stock data

Close
5.08 USD
Market cap
640.95M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States